This meeting was organized by The Transplantation Society with the assistance of an
unconditional education grant from CSL Behring. CSL Behring had no involvement in the …

Advances in multimodal immunotherapy have significantly reduced acute rejection rates and
substantially improved 1-year graft survival following renal transplantation. However, long …

Background A report from a high-volume single center indicated a survival benefit of
receiving a kidney transplant from an HLA-incompatible live donor as compared with …

Kidney allograft rejection can occur in clinically stable patients, but long-term significance is
unknown. We determined whether early recognition of subclinical rejection has long-term …

HLA antigens are polymorphic proteins expressed on donor kidney allograft endothelium
and are critical targets for recipient immune recognition. HLA antibodies are risk factors for …

This study examined outcomes beyond 1 year in eculizumab-treated (EC) positive
crossmatch kidney transplants (+ XMKTx) compared to a historical control group.+ XMKTx …

Over the past decade, several studies have suggested that the complement system has an
active role in both acute and chronic allograft rejection. These studies have been facilitated …

The immunomodulatory capacity of mesenchymal stem or stromal cells (MSC) makes them a
promising tool for treatment of immune disease and organ transplantation. The effects of …

Background More than 40% of patients awaiting a kidney transplant in the UK are sensitised
with human leucocyte antigen (HLA) antibodies. Median time to transplantation for such …

Incompatible live donor kidney transplantation (ILDKT) offers a survival advantage over
dialysis to patients with anti‐HLA donor‐specific antibody (DSA). Program‐specific reports …